These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Expression of the chemokine receptor gene, CCR8, is associated With DUSP22 rearrangements in anaplastic large cell lymphoma. Xing X; Flotte TJ; Law ME; Blahnik AJ; Chng WJ; Huang G; Knudson RA; Ketterling RP; Porcher JC; Ansell SM; Sidhu J; Dogan A; Feldman AL Appl Immunohistochem Mol Morphol; 2015 Sep; 23(8):580-9. PubMed ID: 25390351 [TBL] [Abstract][Full Text] [Related]
23. Histopathological features and outcomes of DUSP22 rearrangement in primary cutaneous anaplastic large cell lymphoma: a case report and review of the literature. Nieto-Benito LM; Parra-Blanco V; Gómez-Navarro Y; Menárguez-Palanca J; Pulido-Pérez A J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):e670-e672. PubMed ID: 34014587 [No Abstract] [Full Text] [Related]
24. Qiu L; Tang G; Li S; Vega F; Lin P; Wang SA; Wang W; Iyer SP; Malpica L; Miranda RN; Konoplev S; Tang Z; Fang H; Medeiros LJ; Xu J Haematologica; 2023 Jun; 108(6):1604-1615. PubMed ID: 36453104 [TBL] [Abstract][Full Text] [Related]
25. Primary cutaneous anaplastic large cell lymphoma with DUSP22-IRF4 rearrangement demonstrating a biphasic histopathologic pattern and a complete natural regression. Kitajima Y; Yamashina M; Hanamoto M; Shijimaya T; Terai S; Nakamaru S; Makimura K; Inoue N; Takeuchi K; Kiyohara T J Dermatol; 2022 Sep; 49(9):e309-e310. PubMed ID: 35560037 [No Abstract] [Full Text] [Related]
26. IRF4/DUSP22-positive anaplastic large cell lymphoma arising in the setting of chronic olecranon bursitis. Ku A; Alobeid B Blood; 2023 Jun; 141(23):2912. PubMed ID: 37289474 [No Abstract] [Full Text] [Related]
27. New developments in non-Hodgkin lymphoid malignancies. Ganapathi KA; Brown LE; Prakash S; Bhargava P Pathology; 2021 Apr; 53(3):349-366. PubMed ID: 33685720 [TBL] [Abstract][Full Text] [Related]
28. ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. Sibon D; Nguyen DP; Schmitz N; Suzuki R; Feldman AL; Gressin R; Lamant L; Weisenburger DD; Rosenwald A; Nakamura S; Ziepert M; Maurer MJ; Bast M; Armitage JO; Vose JM; Tilly H; Jais JP; Savage KJ Haematologica; 2019 Dec; 104(12):e562-e565. PubMed ID: 31004022 [No Abstract] [Full Text] [Related]
29. RNAseq identification of FISH-cryptic BCL6::TP63 rearrangement in ALK-negative anaplastic large-cell lymphoma. Ahmed N; Ketterling RP; Nowakowski GS; Dasari S; Feldman AL Histopathology; 2022 Aug; 81(2):275-278. PubMed ID: 35586895 [No Abstract] [Full Text] [Related]
30. Safety and effective salvage regimen comprising a novel combination of brentuximab vedotin, L-asparaginase, and dexamethasone for refractory anaplastic large cell lymphoma, anaplastic lymphoma kinase negative. Kawamoto K; Suzuki T; Kasami T; Kiryu M; Sone H; Miyoshi H; Ohshima K; Takizawa J Hematol Oncol; 2019 Apr; 37(2):212-214. PubMed ID: 30394560 [No Abstract] [Full Text] [Related]
31. Central nervous system ALK-negative anaplastic large cell lymphoma with IRF4/DUSP22 rearrangement. Magaki S; Satyadev R; Chen Z; Yung KS; Vinters HV; Kinney MC; Said JW Brain Tumor Pathol; 2022 Jan; 39(1):25-34. PubMed ID: 34791573 [TBL] [Abstract][Full Text] [Related]
32. Primary effusion anaplastic large cell lymphoma with indolent clinical course and IRF4/DUSP22 rearrangement: a case report expanding the spectrum of effusion-based lymphoma. Yuan CT; Cheng AL; Hou HA Virchows Arch; 2023 Mar; 482(3):641-645. PubMed ID: 35984488 [TBL] [Abstract][Full Text] [Related]
33. ALK-positive anaplastic large cell lymphoma with an unusual alveolar growth pattern. Yu G; Gao Z; Huang X Int J Clin Exp Pathol; 2014; 7(12):9086-9. PubMed ID: 25674293 [TBL] [Abstract][Full Text] [Related]
34. Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma. Dunleavy K; Pittaluga S; Shovlin M; Roschewski M; Lai C; Steinberg SM; Jaffe ES; Wilson WH Haematologica; 2016 Jan; 101(1):e27-9. PubMed ID: 26518748 [No Abstract] [Full Text] [Related]